← Eichor
Condition: Hgg Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hgg

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progress
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06815029A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Pre
Phase 3 · 62 location(s) · Grifols Therapeutics LLC · NCT05645107Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
Phase 2 · 13 location(s) · Nationwide Children's Hospital · NCT05096481A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patie
NA · 1 location(s) · Daniel Morgenstern · NCT06519682A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) G
Phase 1/Phase 2 · 127 location(s) · National Cancer Institute (NCI) · NCT0509900318F-Fluciclovine PET-MRI in High-grade Glioma
EARLY_Phase 1 · 1 location(s) · Children's Hospital of Philadelphia · NCT05553041Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection
Phase 1/Phase 2 · 1 location(s) · Dushu Lake Hospital Affiliated to Soochow University · NCT06018363A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Phase 2 · 70 location(s) · Fore Biotherapeutics · NCT05503797A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participant
EARLY_Phase 1 · 2 location(s) · St. Joseph's Hospital and Medical Center, Phoenix · NCT06072586CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children a
Phase 1 · 1 location(s) · OX2 Therapeutics · NCT06305910Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
Phase 2 · 6 location(s) · St. Jude Children's Research Hospital · NCT06528691A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced So
Phase 1 · 83 location(s) · Pfizer · NCT05538130Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard
Phase 1 · 1 location(s) · Sunnybrook Health Sciences Centre · NCT07179328A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Rec
Phase 1 · 3 location(s) · Neuregen Therapeutics Co., Ltd. · NCT07710690Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
EARLY_Phase 1 · 1 location(s) · Eben Rosenthal · NCT07210632Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurre
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07544992Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Phase 2 · 20 location(s) · Nationwide Children's Hospital · NCT05843253
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.